Metamizole
| Metamizole | |
|---|---|
| Salts [] | |
|---|---|
| Sodium metamizole | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 311.36 g/mol [1] |
| Predicted LogP | 0 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C13H17N3O4S |
| IUPAC name | [(1,5-dimethyl-3-oxo-2-phenylpyrazol-4-yl)-methylamino]methanesulfonic acid |
| SMILES | CC1=C(C(=O)N(N1C)C2=CC=CC=C2)N(C)CS(=O)(=O)O |
| InChI | InChI=1S/C13H17N3O4S/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11/h4-8H,9H2,1-3H3,(H,18,19,20) |
| InChIKey | LVWZTYCIRDMTEY-UHFFFAOYSA-N |
| CAS number | 50567-35-6 |
| UNII | 934T64RMNJ |
| PubChem CID | 3111 |
| Pharmacokinetics[] | |
|---|---|
| Elimination half-life | 14 minutes (parent compound; IV route); metabolites: 2–4 hour |
| Duration of action | 4–6 hours |
| Metabolism | Liver |
| Excretion | Urine (96%, IV; 85%, oral), faeces (4%, IV). |
| Routes of administration | By mouth, intramuscular, intravenous, rectal |
Metamizole (also known as Metamizol, Methamizole, Novamine sulfone, Methamizole-, (antipyrinylmethylamino)methanesulfonic acid, Methanesulfonic acid, (antipyrinylmethylamino)-, N-Methyl-N-(2,3-dimethyl-5-oxo-1-phenyl-3-pyrazolin-4-yl)aminomethanesulfosaeure, Dolemicin, 256-627-7 or Metamizolum) is a analgesic, antipyretics and cyp3a4 inducer substance of the aniline class.
Chemistry
Salts []
Stereochemistry []
Metamizole is achiral.
Druglikeness
Lipinski's rule of five
Metamizole matches Lipinski's rule of five.Pharmacology
Mechanism of action []
The mechanism of action of metamizole is not fully understood. Its active metabolites, 4-methyl-amino-antipyrine (MAA) and 4-amino-antipyrine (AA), inhibit prostaglandin E2 (PGE<sub>2</sub>)-induced hyperalgesia. It has been suggested that the anti-hyperalgesic effect of MAA is mediated by guanosine 3',5'-cyclic monophosphate (cGMP) activation and ATP-sensitive potassium channel opening, while the effects of AA are associated with the activation of cannabinoid receptor type 1 (CB1). Metamizole is classified in some sources as a weak non-steroidal anti-inflammatory drug (NSAID); however, evidence suggests that its analgesic effects do not depend on its anti-inflammatory properties. Although the inhibition of cyclooxygenase (COX) 2 may play a role in the central nervous system effects of metamizole, reports suggest that metamizole inhibits COX-3 with a higher affinity compared to COX-1 or COX-2. [1]
Subjective effects []
| 0xea / Metamizole [] | |
|---|---|
Routes:
| |
| alina / Metamizole [] | |
|---|---|
Routes:
| |
| emily / Metamizole [] | |
|---|---|
Routes:
| |
| Pilz / Metamizole [] | |
|---|---|
Routes:
| |
Legal status []
- Australia: Metamizole is a Withdrawn.
- Brazil: Metamizole is a OTC.
- Canada: Metamizole is a Veterinary only.[3]
- Germany: Metamizole is Prescription only.[4]
- New Zealand: Metamizole is Prescription only.[5][6]
- United Kingdom: Metamizole is a Withdrawn.
- United States: Metamizole is a Veterinary only (horses).[7]
- European Union: Metamizole is Legally available.
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 3111, Metamizole. Accessed November 20, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/3111
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Metamizole. UNII: 934T64RMNJ. Global Substance Registration System. Accessed November 20, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/934T64RMNJ
Notice of Amendment: Addition of Metamizole (Dipyrone) to the Prescription Drug List (PDL). Government of Canada. 2022-07-18. https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/amendment-metamizole.html
Risikoinformationen - Metamizol (Novalgin, Berlosin, Novaminsulfon, etc.): BfArM weist auf richtige Indikationsstellung und Beachtung von Vorsichtsmaßnahmen und Warnhinweisen hin. Bundesinstitut für Arzneimittel und Medizinprodukte (Federal Institute for Pharmaceuticals and Medical Products). 2009-05-28. https://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RI/2009/RI-metamizol.html
Recent NZ Gazette Notices Relating to Classification. medsafe.govt.nz. 2020-03-06. https://www.medsafe.govt.nz/profs/class/recent.asp
Minutes of the 63rd meeting of the Medicines Classification Committee - 10 Oct 2019. medsafe.govt.nz. 2019-12-04. https://www.medsafe.govt.nz/profs/class/Minutes/2016-2020/mccMin10Oct2019.htm
Zimeta (dipyrone injection) - Veterinarians. FDA. November 26, 2019. https://www.fda.gov/animal-veterinary/product-safety-information/zimeta-dipyrone-injection-veterinarians
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 10:24:51 |
| drugspro | missing (no DrugsPRO reagent data) | 2026-11-20 10:24:47 |
| erowid | missing (no Erowid substance of that name) | 2026-11-20 10:24:47 |
| gsrs | ok | 2026-11-20 10:24:48 |
| hmdb | missing (hmdb.ca refused automated access to HMDB0254502) | 2026-11-20 10:24:47 |
| kegg | ok | 2026-11-20 10:24:48 |
| pubchem | ok | 2026-11-20 10:24:47 |
| missing (no r/tripreports posts mention it) | 2026-11-20 10:24:47 | |
| sider | missing (not in SIDER) | 2026-11-20 10:24:47 |
| structure | ok | 2026-11-20 10:24:47 |
| wikipedia | ok | 2026-11-20 10:24:47 |